| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $3,567,247 | 2 | 100 |
| Smith Nicholas Conrad | PRESIDENT AND CFO | 0 | $0 | 2 | $3.57M | $-3.57M |
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments …
Over the last 12 months, insiders at Alto Neuroscience, Inc. have bought $0 and sold $3.57M worth of Alto Neuroscience, Inc. stock.
On average, over the past 5 years, insiders at Alto Neuroscience, Inc. have bought $190,833 and sold $3.57M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,931 shares for transaction amount of $38,748 was made by Savitz Adam (CHIEF MEDICAL OFFICER) on 2024‑07‑10.
| 2026-09-30 | Sale | Smith Nicholas Conrad | PRESIDENT AND CFO | 24,056 0.0693% | $25.82 | $621,097 | -8.91% | |
| 2026-09-29 | Sale | Smith Nicholas Conrad | PRESIDENT AND CFO | 110,830 0.3158% | $26.58 | $2.95M | -12.26% | |
| 2024-07-10 | Savitz Adam | CHIEF MEDICAL OFFICER | 2,931 0.0326% | $13.22 | $38,748 | -68.16% | ||
| 2024-07-09 | Savitz Adam | CHIEF MEDICAL OFFICER | 12,069 0.1279% | $12.60 | $152,085 | -69.43% |
| Increased Positions | 57 | +69.51% | 9M | +55.77% |
| Decreased Positions | 33 | -40.24% | 1M | -8.96% |
| New Positions | 30 | New | 4M | New |
| Sold Out Positions | 9 | Sold Out | 86,546 | Sold Out |
| Total Postitions | 106 | +29.27% | 25M | +46.81% |
| Alpha Wave Global, Lp | $61,512.00 | 11.96% | 3.71M | 0 | 0% | 2025-09-30 |
| Armistice Capital, Llc | $27,141.00 | 5.28% | 1.64M | +12,000 | +0.74% | 2025-09-30 |
| Point72 Asset Management, L.P. | $22,105.00 | 4.3% | 1.33M | +2,682 | +0.2% | 2025-09-30 |
| Franklin Resources Inc | $19,288.00 | 3.75% | 1.16M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $18,339.00 | 3.57% | 1.11M | +20,702 | +1.91% | 2025-09-30 |
| Vestal Point Capital, Lp | $15,761.00 | 3.07% | 950,000 | 0 | 0% | 2025-09-30 |
| Marshall Wace, Llp | $13,690.00 | 2.66% | 825,225 | -112,182 | -11.97% | 2025-09-30 |
| 72 Investment Holdings, Llc | $11,078.00 | 2.15% | 667,778 | 0 | 0% | 2025-09-30 |
| Alkeon Capital Management Llc | $7,915.00 | 1.54% | 477,101 | 0 | 0% | 2025-09-30 |
| Northern Trust Corp | $7,653.00 | 1.49% | 461,285 | -2,059 | -0.44% | 2025-09-30 |